Imidafenacin

Imidafenacin
  • CAS No.:170105-16-5

Important Notice

  1. This product is a chemical product/pharmaceutical intermediate. It is not a drug, an active pharmaceutical ingredient (API), or a pharmaceutical-grade material. It has not been granted a drug approval number or a Chemical Drug Substance Approval Notice, has not passed drug-related review and approval, and is not manufactured, tested, or released in accordance with pharmaceutical GMP.
  2. This product is intended solely for non-clinical research, process development, quality studies, further chemical processing, or chemical synthesis. It must not be used in drug-product manufacturing, clinical trials, clinical diagnosis, or administration to humans or animals, or be sold, used as an input, submitted for regulatory filing, or released as an API or pharmaceutical material.
  3. The purchaser must not use this product, or supply it to another party, for personal consumption, sports or fitness, weight loss, health supplements, food, or animal feed.
Other grades of this product :
Imidafenacin Basic information
Product Name:Imidafenacin
Synonyms:ONO 8025;KRP-197; ONO-8025;Imidafenacin-d10;Staybla;Uritos;1H-IMidazole-1-butanaMide,2-Methyl-a,a-diphenyl-;IMidafenacin DISCONTINUED-PATENTED PRODUCT;4-(2-METHYL-1H-IMIDAZOL-1-YL)-2,2-DIPHENYLBUTANAMIDE
CAS:170105-16-5
MF:C20H21N3O
MW:319.4
EINECS:689-703-7
Product Categories:Imidazoles, Pyrroles, Pyrazoles, Pyrrolidines;Amines;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:170105-16-5.mol
Imidafenacin Chemical Properties
Melting point 184-187°C
Boiling point 579.7±50.0 °C(Predicted)
density 1.12±0.1 g/cm3(Predicted)
storage temp. Sealed in dry,Room Temperature
solubility DMSO, Methanol
pka15.72±0.50(Predicted)
form Solid
color White
Safety Information
MSDS Information
Imidafenacin Usage And Synthesis
DescriptionImidafenacin, an M3/M1 muscarinic receptor antagonist, was introduced in Japan for the oral treatment of OAB. The majority of OAB symptoms are thought to result from overactivity of the detrusor muscle, which is primarily mediated by acetylcholine-induced stimulation of muscarinic M3 receptors in the bladder. Previously marketed muscarinic antagonists for OAB include propiverine, tolterodine, oxybutynin, trospium, darifenacin, and solifenacin. In vitro, imidafenacin is equally active against M1 and M3 receptors (Kb=0.32 and 0.55nM, respectively), and approximately 10-fold less active against M2 receptors (Kb=4.13nM). Imidafenacin is chemically synthesized in three steps starting with alkylation of diphenylacetonitrile with dibromoethane, followed by condensation with 2-methylimidazole, and hydrolysis of the cyano group to a carboxamide group with 70% sulfuric acid.
Chemical PropertiesWhite Solid
OriginatorKyorin (Japan)
UsesA novel therapeutic agent for overactive bladder with antimuscarinic activity, on mediator release from urothelium and detrusor overactivity induced by cerebral infarction. A muscarinic antagonist.
UsesImidafenacin-d10 is deutirium labelled imidafenacin which is a novel therapeutic agent for overactive bladder with antimuscarinic activity, on mediator release from urothelium and detrusor overactivity induced by cerebral infarction.
Brand nameStaybla
SynthesisDiphenylacetonitrile (53) was alkylated with dibromoethane in the presence of NaNH2 in toluene to give bromide compound 54. The bromide 54 was condensed with 2-methylimidazole in the presence of Et3N in hot DMF to afford 2-methylimidazole derivative 55. Hydrolysis of the cyano group of 55 with 70% sulfuric acid provided imidafenacin (VII).
Imidafenacin Preparation Products And Raw materials

Welcome!

Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.

  • NO. 18 ,Wujiang Road, Wulidian Street, Jiangbei District, Chongqing
  • +86-23-6139-8061 +86-13650506873
  • danny@chemdad.com sales@chemdad.com
  • www.chemdad.com
  • WhatsApp +86-13650506873

Name

phone

company

email

message

Read the full Disclaimer
Payment methods
Google translate: 日本语日本语 한국어한국어 FrançaisFrançais DeutschDeutsch EspañaEspaña TürkiyeTürkiye